Abstract

Th17 cells are key drivers of autoimmune disease. However, the signaling pathways regulating Th17 polarization are poorly understood. Hedgehog signaling regulates cell fate decisions during embryogenesis and adult tissue patterning. Here we find that cell-autonomous Hedgehog signaling, independent of exogenous ligands, selectively drives the polarization of Th17 cells but not other T helper cell subsets. We show that endogenous Hedgehog ligand, Ihh, signals to activate both canonical and non-canonical Hedgehog pathways through Gli3 and AMPK. We demonstrate that Hedgehog pathway inhibition with either the clinically-approved small molecule inhibitor vismodegib or genetic ablation of Ihh in CD4T cells greatly diminishes disease severity in two mouse models of intestinal inflammation. We confirm that Hedgehog pathway expression is upregulated in tissue from human ulcerative colitis patients and correlates with Th17 marker expression. This work implicates Hedgehog signaling in Th17 polarization and intestinal immunopathology and indicates the potential therapeutic use of Hedgehog inhibitors in the treatment of inflammatory bowel disease.

Th17 cells are critical players in the immunopathology of a range of autoimmune diseases. Here the authors implicate Hedgehog signaling in Th17 polarization and in the immunopathology of intestinal inflammation in murine models and suggest therapeutic targeting of Hedgehog signaling in the context of inflammatory bowel disease.

Details

Title
Cell-autonomous Hedgehog signaling controls Th17 polarization and pathogenicity
Author
Hanna, Joachim 1   VIAFID ORCID Logo  ; Beke, Flavio 1   VIAFID ORCID Logo  ; O’Brien, Louise M. 1   VIAFID ORCID Logo  ; Kapeni, Chrysa 1   VIAFID ORCID Logo  ; Chen, Hung-Chang 1   VIAFID ORCID Logo  ; Carbonaro, Valentina 1 ; Kim, Alexander B. 1   VIAFID ORCID Logo  ; Kishore, Kamal 1   VIAFID ORCID Logo  ; Adolph, Timon E. 2   VIAFID ORCID Logo  ; Skjoedt, Mikkel-Ole 3 ; Skjoedt, Karsten 4 ; de la Roche, Marc 5 ; de la Roche, Maike 1   VIAFID ORCID Logo 

 Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK (GRID:grid.498239.d) 
 Medical University Innsbruck, Department of Internal Medicine I, Gastroenterology, Hepatology & Endocrinology, Innsbruck, Austria (GRID:grid.5361.1) (ISNI:0000 0000 8853 2677) 
 Rigshospitalet - University Hospital Copenhagen, Copenhagen, Denmark (GRID:grid.4973.9) (ISNI:0000 0004 0646 7373); University of Copenhagen, Institute of Immunology and Microbiology, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X) 
 University of Southern Denmark, Odense C, Denmark (GRID:grid.10825.3e) (ISNI:0000 0001 0728 0170) 
 Department of Biochemistry, University of Cambridge, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2689409732
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.